Cytotoxic and regulatory properties of circulating Vδ1+ γδ t cells: A new player on the cell therapy field?

Molecular Therapy

Volumn 22, Issue 8, 2014, Pages 1416-1422

  Siegers, Gabrielle M ^a   Lamb, Lawrence S ^b  

^a WESTERN UNIVERSITY   (Canada)

^b Heerskink School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CD1C ANTIGEN; CD1D ANTIGEN; INTERLEUKIN 15 RECEPTOR ALPHA; NATURAL KILLER CELL RECEPTOR NKG2D; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW TRANSPLANTATION; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CELL DEATH; CELL EXPANSION; CELL MIGRATION; CELL STRESS; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; GAMMA DELTA T LYMPHOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOTOXICITY; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PHENOTYPE; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T CELL CULTURE; V DELTA1+ GAMMA DELTA T LYMPHOCYTE; BIOLOGICAL THERAPY; BLOOD; CYTOLOGY; METABOLISM; NEOPLASMS; PROCEDURES; T LYMPHOCYTE;

CELL- AND TISSUE-BASED THERAPY; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 84905447645     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.104     Document Type: Review

References (125)

1. Dougan, M and Dranoff, G (2009). The immune response to tumors. Curr Protoc Immunol Chapter 20: Unit 20. 11.
2. Dougan, M and Dranoff, G (2009). Immune therapy for cancer. Annu Rev Immunol 27: 83-117.
3. Disis, ML, Bernhard, H and Jaffee, EM (2009). Use of tumour-responsive T cells as cancer treatment. Lancet 373: 673-683.
4. Yannelli, JR, Hyatt, C, McConnell, S, Hines, K, Jacknin, L, Parker, L et al. (1996). Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 65: 413-421.
5. Bloom, MB, Perry-Lalley, D, Robbins, PF, Li, Y, el-Gamil, M, Rosenberg, SA et al. (1997). Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185: 453-459.
6. Colella, TA, Bullock, TN, Russell, LB, Mullins, DW, Overwijk, WW, Luckey, CJ et al. (2000). Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 191: 1221-1232.
7. Dudley, ME, Nishimura, MI, Holt, AK and Rosenberg, SA (1999). Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother 22: 288-298.
8. Fleischhauer, K, Tanzarella, S, Russo, V, Sensi, ML, van der Bruggen, P, Bordignon, C et al. (1997). Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. J Immunol 159: 2513-2521.
9. Kawakami, Y, Robbins, PF, Wang, X, Tupesis, JP, Parkhurst, MR, Kang, X et al. (1998). Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 161: 6985-6992.
10. Kim, CJ, Parkinson, DR and Marincola, F (1998). Immunodominance across HLA polymorphism: implications for cancer immunotherapy. J Immunother 21: 1-16.
11. Mateo, L, Gardner, J, Chen, Q, Schmidt, C, Down, M, Elliott, SL et al. (1999). An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J Immunol 163: 4058-4063.
12. Haas, W, Pereira, P and Tonegawa, S (1993). Gamma/delta cells. Annu Rev Immunol 11: 637-685.
13. Hayday, AC (2000). [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18: 975-1026.
14. Allison, JP and Havran, WL (1991). The immunobiology of T cells with invariant gamma delta antigen receptors. Annu Rev Immunol 9: 679-705.
15. Zocchi, MR and Poggi, A (2004). Role of gammadelta T lymphocytes in tumor defense. Front Biosci 9: 2588-2604.
16. Kabelitz, D, Wesch, D and He, W (2007). Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67: 5-8.
17. Girardi, M, Oppenheim, DE, Steele, CR, Lewis, JM, Glusac, E, Filler, R et al. (2001). Regulation of cutaneous malignancy by gammadelta T cells. Science 294: 605-609.
18. Liu, Z, Eltoum, IE, Guo, B, Beck, BH, Cloud, GA and Lopez, RD (2008). Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol 180: 6044-6053.
19. Ferrarini, M, Pupa, SM, Zocchi, MR, Rugarli, C and Ménard, S (1994). Distinct pattern of HSP72 and monomeric laminin receptor expression in human lung cancers infiltrated by gamma/delta T lymphocytes. Int J Cancer 57: 486-490.
20. Choudhary, A, Davodeau, F, Moreau, A, Peyrat, MA, Bonneville, M and Jotereau, F (1995). Selective lysis of autologous tumor cells by recurrent gamma delta tumorinfiltrating lymphocytes from renal carcinoma. J Immunol 154: 3932-3940.
21. Zhao, X, Wei, YQ, Kariya, Y, Teshigawara, K and Uchida, A (1995). Accumulation of gamma/delta T cells in human dysgerminoma and seminoma: roles in autologous tumor killing and granuloma formation. Immunol Invest 24: 607-618.
22. Xu, C, Zhang, H, Hu, H, He, H, Wang, Z, Xu, Y et al. (2007). Gammadelta T cells recognize tumor cells via CDR3delta region. Mol Immunol 44: 302-310.
23. Corvaisier, M, Moreau-Aubry, A, Diez, E, Bennouna, J, Mosnier, JF, Scotet, E et al. (2005). V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol 175: 5481-5488.
24. Zocchi, MR, Ferrarini, M and Rugarli, C (1990). Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas. Eur J Immunol 20: 2685-2689.
25. Bryant, NL, Suarez-Cuervo, C, Gillespie, GY, Markert, JM, Nabors, LB, Meleth, S et al. (2009). Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro-oncology 11: 357-367.
26. Boismenu, R and Havran, WL (1997). An innate view of gamma delta T cells. Curr Opin Immunol 9: 57-63.
27. Chien, YH and Konigshofer, Y (2007). Antigen recognition by gammadelta T cells. Immunol Rev 215: 46-58.
28. O'Brien, RL, Roark, CL, Jin, N, Aydintug, MK, French, JD, Chain, JL et al. (2007). gammadelta T-cell receptors: functional correlations. Immunol Rev 215: 77-88.
29. Morita, CT, Beckman, EM, Bukowski, JF, Tanaka, Y, Band, H, Bloom, BR et al. (1995). Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity 3: 495-507.
30. Bennouna, J, Bompas, E, Neidhardt, EM, Rolland, F, Philip, I, Galéa, C et al. (2008). Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57: 1599-1609.
31. Kobayashi, H, Tanaka, Y, Yagi, J, Osaka, Y, Nakazawa, H, Uchiyama, T et al. (2007). Safety profile and anti-tumor effects of adoptive immunotherapy using gammadelta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56: 469-476.
32. Argentati, K, Re, F, Serresi, S, Tucci, MG, Bartozzi, B, Bernardini, G et al. (2003). Reduced number and impaired function of circulating gamma delta T cells in patients with cutaneous primary melanoma. J Invest Dermatol 120: 829-834.
33. Kabelitz, D, Pechhold, K, Bender, A, Wesselborg, S, Wesch, D, Friese, K et al. (1991). Activation and activation-driven death of human gamma/delta T cells. Immunol Rev 120: 71-88.
34. Tanaka, Y, Morita, CT, Tanaka, Y, Nieves, E, Brenner, MB and Bloom, BR (1995). Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375: 155-158.
35. Tanaka, Y, Sano, S, Nieves, E, De Libero, G, Rosa, D, Modlin, RL et al. (1994). Nonpeptide ligands for human gamma delta T cells. Proc Natl Acad Sci USA 91: 8175-8179.
36. Bukowski, JF, Morita, CT, Tanaka, Y, Bloom, BR, Brenner, MB and Band, H (1995). V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J Immunol 154: 998-1006.
37. Spada, FM, Grant, EP, Peters, PJ, Sugita, M, Melián, A, Leslie, DS et al. (2000). Selfrecognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med 191: 937-948.
38. Leslie, DS, Vincent, MS, Spada, FM, Das, H, Sugita, M, Morita, CT et al. (2002). CD1-mediated gamma/delta T cell maturation of dendritic cells. J Exp Med 196: 1575-1584.
39. Ismaili, J, Olislagers, V, Poupot, R, Fournié, JJ and Goldman, M (2002). Human gamma delta T cells induce dendritic cell maturation. Clin Immunol 103(3 Pt 1): 296-302.
40. Lamb, LS Jr, Henslee-Downey, PJ, Parrish, RS, Godder, K, Thompson, J, Lee, C et al. (1996). Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother 5: 503-509.
41. Godder, KT, Henslee-Downey, PJ, Mehta, J, Park, BS, Chiang, KY, Abhyankar, S et al. (2007). Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 39: 751-757.
42. Groh, V, Rhinehart, R, Secrist, H, Bauer, S, Grabstein, KH and Spies, T (1999). Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96: 6879-6884.
43. Dolstra, H, Fredrix, H, van der Meer, A, de Witte, T, Figdor, C and van de Wielvan Kemenade, E (2001). TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58. 2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant 27: 1087-1093.
44. Duval, M, Yotnda, P, Bensussan, A, Oudhiri, N, Guidal, C, Rohrlich, P et al. (1995). Potential antileukemic effect of gamma delta T cells in acute lymphoblastic leukemia. Leukemia 9: 863-868.
45. Lamb, LS Jr, Musk, P, Ye, Z, van Rhee, F, Geier, SS, Tong, JJ et al. (2001). Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant 27: 601-606.
46. Catellani, S, Poggi, A, Bruzzone, A, Dadati, P, Ravetti, JL, Gobbi, M et al. (2007). Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood 109: 2078-2085.
47. Poggi, A, Venturino, C, Catellani, S, Clavio, M, Miglino, M, Gobbi, M et al. (2004). Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 64: 9172-9179.
48. Schilbach, K, Frommer, K, Meier, S, Handgretinger, R and Eyrich, M (2008). Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy. J Immunother 31: 896-905.
49. Maeurer, M, Zitvogel, L, Elder, E, Storkus, WJ and Lotze, MT (1995). Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat Immun 14: 188-197.
50. Ferrarini, M, Heltai, S, Pupa, SM, Mernard, S and Zocchi, R (1996). Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors. J Natl Cancer Inst 88: 436-441.
51. Maeurer, MJ, Martin, D, Walter, W, Liu, K, Zitvogel, L, Halusczcak, K et al. (1996). Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med 183: 1681-1696.
52. Hayday, A and Vantourout, P (2013). A long-playing CD about the gammadelta TCR repertoire. Immunity 39: 994-996.
53. Vantourout, P and Hayday, A (2013). Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol 13: 88-100.
54. Hannani, D, Ma, Y, Yamazaki, T, Déchanet-Merville, J, Kroemer, G and Zitvogel, L (2012). Harnessing gammadelta T cells in anticancer immunotherapy. Trends Immunol 33: 199-206.
55. Bonneville, M, O'Brien, RL and Born, WK (2010). Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 10: 467-478.
56. Spinozzi, F, Agea, E, Bistoni, O, Forenza, N, Monaco, A, Falini, B et al. (1995). Local expansion of allergen-specific CD30+Th2-type gamma delta T cells in bronchial asthma. Mol Med 1: 821-826.
57. De Rosa, SC, Mitra, DK, Watanabe, N, Herzenberg, LA, Herzenberg, LA and Roederer, M (2001). Vdelta1 and Vdelta2 gammadelta T cells express distinct surface markers and might be developmentally distinct lineages. J Leukoc Biol 70: 518-526.
58. Beldjord, K, Beldjord, C, Macintyre, E, Even, P and Sigaux, F (1993). Peripheral selection of V delta 1+ cells with restricted T cell receptor delta gene junctional repertoire in the peripheral blood of healthy donors. J Exp Med 178: 121-127.
59. Bukowski, JF, Morita, CT and Brenner, MB (1999). Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 11: 57-65.
60. Kunzmann, V, Bauer, E, Feurle, J, Weissinger, F, Tony, HP and Wilhelm, M (2000). Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96: 384-392.
61. Miyagawa, F, Tanaka, Y, Yamashita, S, Mikami, B, Danno, K, Uehara, M et al. (2001). Essential contribution of germline-encoded lysine residues in Jgamma1. 2 segment to the recognition of nonpeptide antigens by human gammadelta T cells. J Immunol 167: 6773-6779.
62. Gober, HJ, Kistowska, M, Angman, L, Jenö, P, Mori, L and De Libero, G (2003). Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197: 163-168.
63. Fu, YX, Vollmer, M, Kalataradi, H, Heyborne, K, Reardon, C, Miles, C et al. (1994). Structural requirements for peptides that stimulate a subset of gamma delta T cells. J Immunol 152: 1578-1588.
64. Laad, AD, Thomas, ML, Fakih, AR and Chiplunkar, SV (1999). Human gamma delta T cells recognize heat shock protein-60 on oral tumor cells. Int J Cancer 80: 709-714.
65. Born, W, Happ, MP, Dallas, A, Reardon, C, Kubo, R, Shinnick, T et al. (1990). Recognition of heat shock proteins and gamma delta cell function. Immunol Today 11: 40-43.
66. Wu, J, Groh, V and Spies, T (2002). T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. J Immunol 169: 1236-1240.
67. Diefenbach, A and Raulet, DH (2002). The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 188: 9-21.
68. Gleimer, M and Parham, P (2003). Stress management: MHC class I and class I-like molecules as reporters of cellular stress. Immunity 19: 469-477.
69. Raulet, DH (2003). Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781-790.
70. Poggi, A, Carosio, R, Fenoglio, D, Brenci, S, Murdaca, G, Setti, M et al. (2004). Migration of V delta 1 and V delta 2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat. Blood 103: 2205-2213.
71. Sutherland, CL, Rabinovich, B, Chalupny, NJ, Brawand, P, Miller, R and Cosman, D (2006). ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 108: 1313-1319.
72. Cosman, D, Müllberg, J, Sutherland, CL, Chin, W, Armitage, R, Fanslow, W et al. (2001). ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123-133.
73. Bauer, S, Groh, V, Wu, J, Steinle, A, Phillips, JH, Lanier, LL et al. (1999). Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
74. Groh, V, Steinle, A, Bauer, S and Spies, T (1998). Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279: 1737-1740.
75. Xu, B, Pizarro, JC, Holmes, MA, McBeth, C, Groh, V, Spies, T et al. (2011). Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA. Proc Natl Acad Sci USA 108: 2414-2419.
76. Porcelli, S, Brenner, MB, Greenstein, JL, Balk, SP, Terhorst, C and Bleicher, PA (1989). Recognition of cluster of differentiation 1 antigens by human CD4-CD8-cytolytic T lymphocytes. Nature 341: 447-450.
77. Faure, F, Jitsukawa, S, Miossec, C and Hercend, T (1990). CD1c as a target recognition structure for human T lymphocytes: analysis with peripheral blood gamma/delta cells. Eur J Immunol 20: 703-706.
78. Agea, E, Russano, A, Bistoni, O, Mannucci, R, Nicoletti, I, Corazzi, L et al. (2005). Human CD1-restricted T cell recognition of lipids from pollens. J Exp Med 202: 295-308.
79. Bai, L, Picard, D, Anderson, B, Chaudhary, V, Luoma, A, Jabri, B et al. (2012). The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vd1 TCR. Eur J Immunol 42: 2505-2510.
80. Russano, AM, Agea, E, Corazzi, L, Postle, AD, De Libero, G, Porcelli, S et al. (2006). Recognition of pollen-derived phosphatidyl-ethanolamine by human CD1d-restricted gamma delta T cells. J Allergy Clin Immunol 117: 1178-1184.
81. Uldrich, AP, Le Nours, J, Pellicci, DG, Gherardin, NA, McPherson, KG, Lim, RT et al. (2013). CD1d-lipid antigen recognition by the gammadelta TCR. Nat Immunol 14: 1137-1145.
82. Luoma, AM, Castro, CD, Mayassi, T, Bembinster, LA, Bai, L, Picard, D et al. (2013). Crystal structure of Vd1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human gammadelta T cells. Immunity 39: 1032-1042.
83. Motohashi, S, Nagato, K, Kunii, N, Yamamoto, H, Yamasaki, K, Okita, K et al. (2009). A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182: 2492-2501.
84. Yamasaki, K, Horiguchi, S, Kurosaki, M, Kunii, N, Nagato, K, Hanaoka, H et al. (2011). Induction of NKT cell-specific immune responses in cancer tissues after NKT celltargeted adoptive immunotherapy. Clin Immunol 138: 255-265.
85. Richter, J, Neparidze, N, Zhang, L, Nair, S, Monesmith, T, Sundaram, R et al. (2013). Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 121: 423-430.
86. Hviid, L, Akanmori, BD, Loizon, S, Kurtzhals, JA, Ricke, CH, Lim, A et al. (2000). High frequency of circulating gamma delta T cells with dominance of the v(delta)1 subset in a healthy population. Int Immunol 12: 797-805.
87. Qi, J, Zhang, J, Zhang, S, Cui, L and He, W (2003). Immobilized MICA could expand human Vdelta1 gammadelta T cells in vitro that displayed major histocompatibility complex class I chain-related A-dependent cytotoxicity to human epithelial carcinomas. Scand J Immunol 58: 211-220.
88. Correia, DV, Fogli, M, Hudspeth, K, da Silva, MG, Mavilio, D and Silva-Santos, B (2011). Differentiation of human peripheral blood Vd1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118: 992-1001.
89. Glatzel, A, Wesch, D, Schiemann, F, Brandt, E, Janssen, O and Kabelitz, D (2002). Patterns of chemokine receptor expression on peripheral blood gamma delta T lymphocytes: strong expression of CCR5 is a selective feature of V delta 2/V gamma 9 gamma delta T cells. J Immunol 168: 4920-4929.
90. Loetscher, P, Uguccioni, M, Bordoli, L, Baggiolini, M, Moser, B, Chizzolini, C et al. (1998). CCR5 is characteristic of Th1 lymphocytes. Nature 391: 344-345.
91. Juffermans, NP, Paxton, WA, Dekkers, PE, Verbon, A, de Jonge, E, Speelman, P et al. (2000). Up-regulation of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells during human endotoxemia and after stimulation with (myco)bacterial antigens: the role of cytokines. Blood 96: 2649-2654.
92. Zarogoulidis, P, Katsikogianni, F, Tsiouda, T, Sakkas, A, Katsikogiannis, N and Zarogoulidis, K (2014). Interleukin-8 and interleukin-17 for cancer. Cancer Invest 32: 197-205.
93. Zhou, J, Kang, N, Cui, L, Ba, D and He, W (2012). Anti-gammadelta TCR antibodyexpanded gammadelta T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cell Mol Immunol 9: 34-44.
94. Devaud, C, Bilhere, E, Loizon, S, Pitard, V, Behr, C, Moreau, JF et al. (2009). Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model. Cancer Res 69: 3971-3978.
95. Lança, T, Costa, MF, Gonçalves-Sousa, N, Rei, M, Grosso, AR, Penido, C et al. (2013). Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic gammadelta T lymphocytes to tumor beds. J Immunol 190: 6673-6680.
96. Lamb, LS Jr, Gee, AP, Hazlett, LJ, Musk, P, Parrish, RS, O'Hanlon, TP et al. (1999). Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy 1: 7-19.
97. Fujishima, N, Hirokawa, M, Fujishima, M, Yamashita, J, Saitoh, H, Ichikawa, Y et al. (2007). Skewed T cell receptor repertoire of Vdelta1(+) gammadelta T lymphocytes after human allogeneic haematopoietic stem cell transplantation and the potential role for Epstein-Barr virus-infected B cells in clonal restriction. Clin Exp Immunol 149: 70-79.
98. Meeh, PF, King, M, O'Brien, RL, Muga, S, Buckhalts, P, Neuberg, R et al. (2006). Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother 55: 1072-1080.
99. Knight, A, Madrigal, AJ, Grace, S, Sivakumaran, J, Kottaridis, P, Mackinnon, S et al. (2010). The role of Vd2-negative gammadelta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 116: 2164-2172.
100. Halary, F, Pitard, V, Dlubek, D, Krzysiek, R, de la Salle, H, Merville, P et al. (2005). Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirusinfected cells and tumor intestinal epithelial cells. J Exp Med 201: 1567-1578.
101. Déchanet, J, Merville, P, Lim, A, Retière, C, Pitard, V, Lafarge, X et al. (1999). Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest 103: 1437-1449.
102. Pitard, V, Roumanes, D, Lafarge, X, Couzi, L, Garrigue, I, Lafon, ME et al. (2008). Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection. Blood 112: 1317-1324.
103. Willcox, CR, Pitard, V, Netzer, S, Couzi, L, Salim, M, Silberzahn, T et al. (2012). Cytomegalovirus and tumor stress surveillance by binding of a human gammadelta T cell antigen receptor to endothelial protein C receptor. Nat Immunol 13: 872-879.
104. Knight, A, Arnouk, H, Britt, W, Gillespie, GY, Cloud, GA, Harkins, L et al. (2013). CMVindependent lysis of glioblastoma by ex vivo expanded/activated Vd1+ gammadelta T cells. PLoS ONE 8: e68729.
105. Muntasell, A, Magri, G, Pende, D, Angulo, A and López-Botet, M (2010). Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. Blood 115: 5170-5179.
106. Bennett, NJ, Ashiru, O, Morgan, FJ, Pang, Y, Okecha, G, Eagle, RA et al. (2010). Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus. J Immunol 185: 1093-1102.
107. Rölle, A, Mousavi-Jazi, M, Eriksson, M, Odeberg, J, Söderberg-Nauclér, C, Cosman, D et al. (2003). Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol 171: 902-908.
108. Schilbach, KE, Geiselhart, A, Wessels, JT, Niethammer, D and Handgretinger, R (2000). Human gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells. J Immunother 23: 536-548.
109. Cordova, A, Toia, F, La Mendola, C, Orlando, V, Meraviglia, S, Rinaldi, G et al. (2012). Characterization of human gammadelta T lymphocytes infiltrating primary malignant melanomas. PLoS ONE 7: e49878.
110. Nishio, N, Fujita, M, Tanaka, Y, Maki, H, Zhang, R, Hirosawa, T et al. (2012). Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human gammadelta T cells. J Immunother 35: 598-606.
111. Peng, G, Wang, HY, Peng, W, Kiniwa, Y, Seo, KH and Wang, RF (2007). Tumorinfiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27: 334-348.
112. Ma, C, Zhang, Q, Ye, J, Wang, F, Zhang, Y, Wevers, E et al. (2012). Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer. J Immunol 189: 5029-5036.
113. Ye, J, Ma, C, Hsueh, EC, Eickhoff, CS, Zhang, Y, Varvares, MA et al. (2013). Tumorderived gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol 190: 2403-2414.
114. Traxlmayr, MW, Wesch, D, Dohnal, AM, Funovics, P, Fischer, MB, Kabelitz, D et al. (2010). Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. J Immunother 33: 40-52.
115. Siegers, GM, Dhamko, H, Wang, XH, Mathieson, AM, Kosaka, Y, Felizardo, TC et al. (2011). Human Vd1 gammadelta T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 13: 753-764.
116. Hua, F, Kang, N, Gao, YA, Cui, LX, Ba, DN and He, W (2013). Potential regulatory role of in vitro-expanded Vd1 T cells from human peripheral blood. Immunol Res 56: 172-180.
117. Donia, M, Ellebaek, E, Andersen, MH, Straten, PT and Svane, IM (2012). Analysis of Vd1 T cells in clinical grade melanoma-infiltrating lymphocytes. Oncoimmunology 1: 1297-1304.
118. Fournié, JJ, Sicard, H, Poupot, M, Bezombes, C, Blanc, A, Romagné, F et al. (2013). What lessons can be learned from gammadelta T cell-based cancer immunotherapy trials? Cell Mol Immunol 10: 35-41.
119. Lopez, RD, Xu, S, Guo, B, Negrin, RS and Waller, EK (2000). CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogeninduced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 96: 3827-3837.
120. Guo, B, Hollmig, K and Lopez, RD (2001). In vitro activity of apoptosis-resistant human gd-T cells against solid malignances. J Clin Oncol 20: 267 (abstract).
121. Knight, A, Mackinnon, S and Lowdell, MW (2012). Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 14: 1110-1118.
122. Siegers, GM, Felizardo, TC, Mathieson, AM, Kosaka, Y, Wang, XH, Medin, JA et al. (2011). Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model. PLoS ONE 6: e16700.
123. Siegers, GM, Ribot, EJ, Keating, A and Foster, PJ (2013). Extensive expansion of primary human gamma delta T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI. Cancer Immunol Immunother 62: 571-583.
124. Drobyski, WR, Majewski, D and Hanson, G (1999). Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs. -host disease. Biol Blood Marrow Transplant 5: 222-230.
125. Shi, J, Tricot, G, Szmania, S, Rosen, N, Garg, TK, Malaviarachchi, PA et al. (2008). Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 143: 641-653.